SILCS-MC validation highlights Full text
New SILCS-MC Study Demonstrates Improved Performance with Machine Learning Optimization May 16, 2019, Baltimore, MD – SilcsBio, a company that develops commercial software and related services for structure-based drug design, today announced that established Site-identification by ligand competitive saturation-Monte Carlo (SILCS-MC) approaches were applied to seven protein targets and 551 ligands, correctly predicting[…]
Baltimore, MD, 26 April, 2019 In ongoing efforts to improve the coverage of the CGenFF program, version 2.3.0 of the CGenFF program improves support for a variety of molecules via explicit parametrization of the molecules outlined below and features improvements for halogen-protein interactions. Molecules explicitly parametrized The functional groups in these molecules were previously accessible[…]
FOR IMMEDIATE RELEASE: April 11, 2019 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Receives NIH Funding to Expand Offerings in Biologics Baltimore, Maryland: SilcsBio, LLC announced today a $225,000 award from the National Institutes of Health to expand on its broadly used software, SILCS, to enable its use with biological therapeutics, especially for[…]
There are no job opportunities available at this time. Please check back again.
FOR IMMEDIATE RELEASE: July 12, 2018 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design Software July 12, 2018 Baltimore, Maryland: SilcsBio, LLC (SilcsBio) announced today the issuance of a US patent covering key elements of SilcsBio’s drug design software. The SilcsBio software is broadly used[…]